10-Q Filing

BIO-TECHNE CORP CIK: 842023 Q2 2023

Filing Information

Form Type	10-Q
Accession Number	`0001558370-23-000979`
Period End Date	20221231
Filing Date	20230207
Fiscal Year	2023
Fiscal Period	Q2
XBRL Instance	tmb-20221231x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 92 Income Statement 96 Cash Flow Statement 88

Balance Sheet 92 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$2.57M	USD	Point-in-time
Accounts receivable, allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$3.25M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$164.68M	USD	Point-in-time
Undesignated capital stock, no par (in dollars per share)	`UndesignatedCapitalStockNoParValue`	-	USD	Point-in-time
Undesignated capital stock, no par (in dollars per share)	`UndesignatedCapitalStockNoParValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$172.57M	USD	Point-in-time
Undesignated capital stock, shares authorized (in shares)	`UndesignatedCapitalStockSharesAuthorized`	5.00M	shares	Point-in-time
Short-term available-for-sale investments	`ShortTermInvestments`	$32.07M	USD	Point-in-time
Undesignated capital stock, shares authorized (in shares)	`UndesignatedCapitalStockSharesAuthorized`	5.00M	shares	Point-in-time
Short-term available-for-sale investments	`ShortTermInvestments`	$74.46M	USD	Point-in-time
Undesignated capital stock, shares issued (in shares)	`UndesignatedCapitalStockSharesIssued`	0.00	shares	Point-in-time
Undesignated capital stock, shares issued (in shares)	`UndesignatedCapitalStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, less allowance for doubtful accounts of $3,250 and $2,568, respectively	`AccountsReceivableNetCurrent`	$194.55M	USD	Point-in-time
Accounts receivable, less allowance for doubtful accounts of $3,250 and $2,568, respectively	`AccountsReceivableNetCurrent`	$184.76M	USD	Point-in-time
Undesignated capital stock, shares outstanding (in shares)	`UndesignatedCapitalStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$141.12M	USD	Point-in-time
Undesignated capital stock, shares outstanding (in shares)	`UndesignatedCapitalStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$160.23M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$23.43M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$22.86M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$605.56M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$565.18M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	156.64M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	157.09M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$223.24M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$223.85M	USD	Point-in-time
Right of use asset	`OperatingLeaseRightOfUseAsset`	$83.94M	USD	Point-in-time
Right of use asset	`OperatingLeaseRightOfUseAsset`	$65.56M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	156.64M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	157.09M	shares	Point-in-time
Goodwill	`Goodwill`	$869.59M	USD	Point-in-time
Goodwill	`Goodwill`	$822.10M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$531.52M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$567.65M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$46.83M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$53.19M	USD	Point-in-time
Total assets	`Assets`	$2.29B	USD	Point-in-time
Total assets	`Assets`	$2.36B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$33.87M	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$24.10M	USD	Point-in-time
Salaries, wages and related accruals	`EmployeeRelatedLiabilitiesCurrent`	$28.63M	USD	Point-in-time
Salaries, wages and related accruals	`EmployeeRelatedLiabilitiesCurrent`	$61.95M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$17.89M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$16.28M	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityCurrent`	$23.41M	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityCurrent`	$21.81M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$25.28M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$13.24M	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$10.97M	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$11.93M	USD	Point-in-time
Current portion of long-term debt obligations	`LongTermDebtCurrent`	$12.50M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.32M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.24M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$176.02M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$128.40M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$98.99M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$111.38M	USD	Point-in-time
Long-term debt obligations	`LongTermDebtAndCapitalLeaseObligations`	$243.41M	USD	Point-in-time
Long-term debt obligations	`LongTermDebtAndCapitalLeaseObligations`	$200.00M	USD	Point-in-time
Long-term contingent consideration payable	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$7.00M	USD	Point-in-time
Long-term contingent consideration payable	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$5.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$58.13M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$78.18M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$12.24M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$11.34M	USD	Point-in-time
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	`UndesignatedCapitalStockValue`	-	USD	Point-in-time
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	`UndesignatedCapitalStockValue`	-	USD	Point-in-time
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,093,879 and 156,644,212, respectively(1)	`CommonStockValue`	$1.57M	USD	Point-in-time
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,093,879 and 156,644,212, respectively(1)	`CommonStockValue`	$1.57M	USD	Point-in-time
Additional paid-in capital(1)	`AdditionalPaidInCapitalCommonStock`	$700.68M	USD	Point-in-time
Additional paid-in capital(1)	`AdditionalPaidInCapitalCommonStock`	$652.47M	USD	Point-in-time
Retained earnings(1)	`RetainedEarningsAccumulatedDeficit`	$1.20B	USD	Point-in-time
Retained earnings(1)	`RetainedEarningsAccumulatedDeficit`	$1.12B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-75.12M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-75.20M	USD	Point-in-time
Total Bio-Techne's shareholders' equity	`StockholdersEquity`	$1.70B	USD	Point-in-time
Total Bio-Techne's shareholders' equity	`StockholdersEquity`	$1.83B	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-759.00K	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.65B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.70B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.57B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.83B	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.70B	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$2.36B	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$2.29B	USD	Point-in-time

Income Statement 96 line items

Line Item	Tag	Value	Unit	Period
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$271.58M	USD	1 Quarter
Stock dividend stock spilt	`StockholdersEquityNoteStockSplitConversionRatio1`	4.00	pure	Point-in-time
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$269.28M	USD	1 Quarter
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$527.00M	USD	2 Qtrs
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$541.24M	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$172.31M	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$178.28M	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$85.58M	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$88.22M	USD	1 Quarter
Gross margin	`GrossProfit`	$362.96M	USD	2 Qtrs
Gross margin	`GrossProfit`	$183.69M	USD	1 Quarter
Gross margin	`GrossProfit`	$183.36M	USD	1 Quarter
Gross margin	`GrossProfit`	$354.69M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$93.01M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$192.39M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$100.69M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$186.87M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$42.25M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$46.36M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$22.46M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$20.65M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$238.75M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$229.12M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$115.47M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$121.34M	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$62.35M	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$124.21M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$125.57M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$67.89M	USD	1 Quarter
Other income (expense)	`NonoperatingIncomeExpense`	$27.99M	USD	2 Qtrs
Other income (expense)	`NonoperatingIncomeExpense`	$-1.46M	USD	1 Quarter
Other income (expense)	`NonoperatingIncomeExpense`	$45.94M	USD	2 Qtrs
Other income (expense)	`NonoperatingIncomeExpense`	$23.83M	USD	1 Quarter
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$153.56M	USD	2 Qtrs
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$86.18M	USD	1 Quarter
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$170.15M	USD	2 Qtrs
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$66.43M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$14.12M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$12.52M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$30.41M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$16.42M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$68.98M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$141.04M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$50.01M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$139.74M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$89.73M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$72.06M	USD	1 Quarter
Net earnings (loss) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$179.00K	USD	2 Qtrs
Net earnings (loss) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-8.75M	USD	2 Qtrs
Net earnings (loss) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-8.11M	USD	1 Quarter
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$139.56M	USD	2 Qtrs
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$149.79M	USD	2 Qtrs
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$50.01M	USD	1 Quarter
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$80.17M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-4.09M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-6.72M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$17.37M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.92M	USD	1 Quarter
Foreign currency translation reclassified to earnings with Eminence deconsolidation	`OtherComprehensiveIncomeLossReleaseOfForeignCurrencyTransactionAndTranslationFromSalePortionAttributableToParent`	$119.00K	USD	1 Quarter
Foreign currency translation reclassified to earnings with Eminence deconsolidation	`OtherComprehensiveIncomeLossReleaseOfForeignCurrencyTransactionAndTranslationFromSalePortionAttributableToParent`	$119.00K	USD	2 Qtrs
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$2.88M	USD	1 Quarter
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$4.57M	USD	2 Qtrs
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$4.01M	USD	2 Qtrs
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-685.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$16.68M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$4.81M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-6.96M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-2.16M	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$42.00K	USD	2 Qtrs
Other comprehensive income (loss) attributable to noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$66.00K	USD	1 Quarter
Other comprehensive income (loss) attributable to noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$-33.00K	USD	2 Qtrs
Other comprehensive income (loss) attributable to noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$27.00K	USD	2 Qtrs
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$75.00K	USD	2 Qtrs
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$16.68M	USD	1 Quarter
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$4.74M	USD	1 Quarter
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-2.18M	USD	2 Qtrs
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$66.69M	USD	1 Quarter
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$84.92M	USD	1 Quarter
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$147.60M	USD	2 Qtrs
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$139.63M	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.95	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.89	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.32	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.51	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.86	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$0.91	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$0.31	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.49	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	157.24M	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	156.89M	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	156.81M	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	157.01M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	164.64M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	161.77M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	161.75M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	164.83M	shares	1 Quarter

Cash Flow Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net earnings, including noncontrolling interest	`ProfitLoss`	$68.98M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$141.04M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$50.01M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$139.74M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$89.73M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$72.06M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$53.34M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$49.84M	USD	2 Qtrs
Costs recognized on sale of acquired inventory	`FairValueWriteUpOfAcquiredInventory`	$400.00K	USD	2 Qtrs
Costs recognized on sale of acquired inventory	`FairValueWriteUpOfAcquiredInventory`	$1.60M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-6.37M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$7.23M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$31.20M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$25.71M	USD	2 Qtrs
Fair value adjustment to contingent consideration payable	`FairValueAdjustmentToContingentConsiderationPayable`	$-16.40M	USD	2 Qtrs
Fair value adjustment to contingent consideration payable	`FairValueAdjustmentToContingentConsiderationPayable`	$-8.60M	USD	2 Qtrs
Contingent consideration payments - operating	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-3.30M	USD	2 Qtrs
(Gain) Loss on investment, net	`GainOnSaleOfInvestments`	$37.18M	USD	2 Qtrs
Fair value adjustment on available for sale investments	`FairValueAdjustmentOnAvailableForSaleSecurities`	$-839.00K	USD	2 Qtrs
Fair value adjustment on available for sale investments	`FairValueAdjustmentOnAvailableForSaleSecurities`	$-33.67M	USD	2 Qtrs
Asset impairment restructuring	`AssetImpairmentRestructuringCharge`	$546.00K	USD	2 Qtrs
Asset impairment restructuring	`AssetImpairmentRestructuringCharge`	-	USD	2 Qtrs
Eminence impairment	`GoodwillAndIntangibleAssetImpairment`	$18.71M	USD	2 Qtrs
Gain on sale of Eminence	`GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee`	$11.68M	USD	2 Qtrs
Gain on sale of Eminence	`GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee`	-	USD	2 Qtrs
Leases, net	`NoncashPortionOfLeaseExpense`	$640.00K	USD	2 Qtrs
Leases, net	`NoncashPortionOfLeaseExpense`	$-501.00K	USD	2 Qtrs
Other operating activity	`OtherOperatingActivitiesCashFlowStatement`	$383.00K	USD	2 Qtrs
Other operating activity	`OtherOperatingActivitiesCashFlowStatement`	$112.00K	USD	2 Qtrs
Trade accounts and other receivables, net	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-11.43M	USD	2 Qtrs
Trade accounts and other receivables, net	`IncreaseDecreaseInAccountsAndOtherReceivables`	$9.35M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$18.36M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$8.70M	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$7.03M	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$2.00M	USD	2 Qtrs
Trade accounts payable, accrued expenses, contract liabilities, and other	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-175.00K	USD	2 Qtrs
Trade accounts payable, accrued expenses, contract liabilities, and other	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-11.54M	USD	2 Qtrs
Salaries, wages and related accruals	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-33.27M	USD	2 Qtrs
Salaries, wages and related accruals	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-10.41M	USD	2 Qtrs
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-6.10M	USD	2 Qtrs
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$13.44M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$120.47M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$149.43M	USD	2 Qtrs
Proceeds from maturities of available-for-sale investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$12.45M	USD	2 Qtrs
Proceeds from maturities of available-for-sale investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$26.51M	USD	2 Qtrs
Purchases of available-for-sale investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$20.50M	USD	2 Qtrs
Purchases of available-for-sale investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$13.50M	USD	2 Qtrs
Proceeds from sale of CCXI investment	`ProceedsFromSaleOfEquitySecuritiesFvNi`	$73.22M	USD	2 Qtrs
Additions to property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$16.24M	USD	2 Qtrs
Additions to property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$15.66M	USD	2 Qtrs
Acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$101.18M	USD	2 Qtrs
Proceeds from sale of Eminence	`ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries`	$17.82M	USD	2 Qtrs
Investment of forward purchase contract	`PaymentsForDerivativeInstrumentInvestingActivities`	$25.00M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-42.29M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-19.80M	USD	2 Qtrs
Cash dividends	`PaymentsOfDividendsCommonStock`	$25.07M	USD	2 Qtrs
Cash dividends	`PaymentsOfDividendsCommonStock`	$25.11M	USD	2 Qtrs
Proceeds from stock option exercises	`ProceedsFromStockOptionsExercised`	$16.98M	USD	2 Qtrs
Proceeds from stock option exercises	`ProceedsFromStockOptionsExercised`	$56.50M	USD	2 Qtrs
Re-purchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$19.56M	USD	2 Qtrs
Re-purchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$41.29M	USD	2 Qtrs
Borrowings under line-of-credit agreement	`ProceedsFromLongTermLinesOfCredit`	$50.00M	USD	2 Qtrs
Borrowings under line-of-credit agreement	`ProceedsFromLongTermLinesOfCredit`	$449.66M	USD	2 Qtrs
Repayments of long-term debt	`RepaymentsOfLinesOfCredit`	$505.66M	USD	2 Qtrs
Repayments of long-term debt	`RepaymentsOfLinesOfCredit`	$109.25M	USD	2 Qtrs
Contingent consideration payments - financing	`PaymentForContingentConsiderationLiabilityFinancingActivities`	$700.00K	USD	2 Qtrs
Contingent consideration payments - financing	`PaymentForContingentConsiderationLiabilityFinancingActivities`	-	USD	2 Qtrs
Taxes paid on RSUs and net share settlements	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$23.25M	USD	2 Qtrs
Taxes paid on RSUs and net share settlements	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$17.85M	USD	2 Qtrs
Other financing activity	`ProceedsFromPaymentsForOtherFinancingActivities`	$-2.46M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-104.00M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-93.06M	USD	2 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-1.32M	USD	2 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-4.55M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-7.88M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$12.75M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$211.84M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$164.68M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$199.09M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$172.57M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$211.84M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$164.68M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$199.09M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$172.57M	USD	Point-in-time
Cash paid for income taxes	`IncomeTaxesPaid`	$15.37M	USD	2 Qtrs
Cash paid for income taxes	`IncomeTaxesPaid`	$26.41M	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$6.14M	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$5.62M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.